Skip to main content
. 2024 May 31;44(Suppl 1):182–197. doi: 10.7705/biomedica.6951

Figure 1. Mortality in patients according to sinus rhythm and triple therapy [angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), beta-blocker and mineralocorticoid receptor antagonist (MRA)] by type 2 diabetes mellitus group.

Figure 1